Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota 55455

8 studies enrolling now · 141 studies all time

What they study most

AML, Acquired Resistance to KRAS G12C Inhibitor, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Acute Myelogenous Leukemia (AML), Acute Myeloid Leukemia, Acyl-CoA Oxidase Deficiency, Adenocarcinoma of Lung, Adrenocortical Carcinoma, Adrenoleukodystrophy

Studies at this site

• Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer — Recruiting now
• Role of Acetaldehyde in the Development of Oral Cancer — Recruiting now
• EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma — Recruiting now
• Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC) — Recruiting now
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies — Recruiting now
• Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units — Recruiting now
• Auto Stem Cell Transplant for Lymphoma Patients — Recruiting now
• Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma — Recruiting now
• RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial — Recruiting now
• Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis — Running, not enrolling
• MT2022-01: MSCs for ALD — Paused
• Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies — Running, not enrolling
• NF-1, Nutraceutical Intervention — Running, not enrolling
• Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS — Running, not enrolling
• Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma — Completed
• Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T — Completed
• A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering — Completed
• CISH Inactivated TILs in the Treatment of NSCLC — Withdrawn before enrolling
• A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors — Stopped early
• Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel — Running, not enrolling
• MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis — Running, not enrolling
• A Phase 1 Study of [225Ac]-FPI-1434 Injection — Stopped early
• HCW9218 in Select Advanced Solid Tumors — Completed
• Assessing the Time Demands of Cancer — Running, not enrolling
• Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia — Completed
• Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL — Stopped early
• MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer — Stopped early
• Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant — Stopped early
• Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS — Stopped early
• Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) — Completed
• Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer — Running, not enrolling
• QuitGuide for American Indians: Aims 2 & 3 — Completed
• FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia — Completed
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer — Completed
• A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS) — Stopped early
• CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies — Completed
• Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL — Withdrawn before enrolling
• App-Assisted Day Reconstruction to Reduce Logistic Toxicity in Cancer — Completed
• EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity — Completed
• Auto Transplant for High Risk or Relapsed Solid or CNS Tumors — Completed
• High Dose Chemotherapy and Autologous Transplant for Neuroblastoma — Completed
• Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors — Stopped early
• Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia — Stopped early
• Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS — Completed
• Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) — Completed
• IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer — Completed
• Exemestane in Post-Menopausal Women With NSCLC — Completed
• Methods Project 4: Clinical Trial — Completed
• REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies — Stopped early
• GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies — Stopped early